FGFR1 and cholangiocarcinoma: Erdafitinib, an inhibitor of FGFR1/2/3/4, was examined in a phase IIa study in Asia with 22 CCA patients, resulting in an ORR of 40.9%, a mPFS of 5.6 months, and a mOS of 40.2 months [81].